Juvenescence Ltd Amends AgeX Therapeutics Stake Filing

TL;DR

Juvenescence Ltd filed an amendment (33) on 3/7/24 for AgeX Therapeutics (AGEX) - still a major player.

AI Summary

Juvenescence Ltd, through its filing amendment dated March 7, 2024, has updated its Schedule 13D regarding AgeX Therapeutics, Inc. The filing indicates a change in beneficial ownership, with Juvenescence Ltd continuing to hold a significant stake in AgeX Therapeutics. Specific details on the exact percentage change or new holdings are not immediately clear from this amendment alone, but it signifies ongoing activity by Juvenescence in AgeX Therapeutics.

Why It Matters

This amendment signals continued significant investor interest and potential strategic involvement from Juvenescence Ltd in AgeX Therapeutics, which could impact the company's future direction and stock performance.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant ownership changes or intentions by large shareholders, which can lead to volatility and strategic shifts for the company.

Key Numbers

• Amendment No. 33 — Filing Amendment Number (Indicates this is a significant update to previous filings.)

Key Players & Entities

• Juvenescence Ltd (company) — Filing entity and significant shareholder
• AgeX Therapeutics, Inc. (company) — Subject company
• David Gill (person) — Person authorized to receive notices

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $500,000 — Issuer each in the principal amount of $500,000. SIGNATURES After reasonable inquiry

Filing Documents

• tm248134d1_sc13da.htm (SC 13D/A) — 42KB
• 0001104659-24-031701.txt ( ) — 44KB

of the Original Statement is hereby amended and restated in

Item 5 of the Original Statement is hereby amended and restated in its entirety to read as follows: (a)The Reporting Persons beneficially owns an aggregate of 92,399,774 shares of Common Stock, representing (i) 66,447,499 shares of Common Stock held directly by JuvVentures (UK) Limited, (ii) 308,565 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the New Facility (as defined below), (iii) 10,357,086 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the A&R Secured Note (as defined below) and (iv) 15,286,624 shares of Common Stock that may be issued upon conversion of outstanding amounts under the A&R Secured Note at the closing price of the Common Stock on March 4, 2024 . This aggregate amount represents approximately 81.1% of the Issuer’s outstanding common stock, based upon 37,951,261 shares outstanding as of November 6, 2023, as reported on the Issuer’s Annual Report filed on Form 10-Q on November 14, 2023, and giving effect to the exercise of the Warrants, conversion of amounts outstanding under the A&R Secured Note and conversion of the outstanding shares of the Series A Preferred Stock and Series B Preferred Stock. (b)The information in Items 7 through 10 of each cover page is incorporated by reference into this Item 5(b). (c)Except for the information set forth in Item 6, which is incorporated by reference into this Item 5(c), the Reporting Persons have effected no transactions relating to the Common Stock during the past 60 days. (d) - (e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

of the Original Statement is hereby supplemented as follows

Item 6 of the Original Statement is hereby supplemented as follows: On March 5, 2024, the Reporting Person funded additional advances to the Issuer each in the principal amount of $500,000.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct. Date: March 7, 2024 JUVENESCENCE LIMITED By: /s/ Gregory H. Bailey Name: Gregory H. Bailey Title: Executive Chairman Date: March 7, 2024 JuvVentures (UK) Limited By: /s/ David Gill Name: David Gill Title: Director

View Full Filing

View this SC 13D/A filing on SEC EDGAR